asc42
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 27, 2020 (NCT04679129)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05464628 | Phase 1 | Aug 8, 2022 | Gannex Pharma Co., Ltd. |
| NCT05190523 | Phase 2 | Apr 6, 2022 | Gannex Pharma Co., Ltd. |
| NCT05107778 | Phase 2 | Dec 17, 2021 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT04965337 | Phase 1 | Jul 11, 2021 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT04679129 | Phase 1 | Dec 27, 2020 | Gannex Pharma Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gannex Pharma Co., Ltd. | For profit | 3 | 3 | 2 | 2020 |
| Ascletis Pharmaceuticals Co., Ltd. | For profit | 2 | 2 | 2 | 2021 |
2 organizations
Page 1 / 1